Navigation Links
Gleevec May Disrupt Ovarian Function

Benefits still outweigh potential infertility risks, experts say

WEDNESDAY, March 5 (HealthDay News) -- Although it's a much more targeted treatment than standard chemotherapy, the effective and much-touted leukemia drug, Gleevec, isn't without side effects.

In women still in their reproductive years, imatinib (Gleevec) might damage the chances of having a baby in the future, according to a case report published as a letter in the March 6 issue of the New England Journal of Medicine.

"Although the odds are not known, it is possible that imatinib and drugs with a similar mode of action may impair fertility," said one of the letter's authors, Dr. Constantinos Christopoulos, deputy director of the 1st department of internal medicine at Amalia Fleming General Hospital in Athens, Greece. "It is not known whether imatinib-induced infertility is reversible."

However, Christopoulos was also quick to point out that this was only a single case report of premature ovarian failure, and it can be difficult to establish the exact cause of the condition.

"Imatinib is a very effective drug that has revolutionized the treatment of chronic myeloid leukemia (CML), but knowledge of the effects of its long-term administration is still limited, and close medical surveillance of patients receiving the drug is mandatory," he said.

The patient Christopoulos and his colleagues reported on was a 28-year-old female who had Philadelphia chromosome-positive CML. Each year in the United States, just under 5,000 people are diagnosed with this type of cancer, according to the Leukemia and Lymphoma Society.

She was initially given 400 milligrams of Gleevec daily. About one year into her treatment, the dose of Gleevec was increased to 600 milligrams per day, because she still had some cancer cells. She didn't have any severe side effects due to the treatment, though she experienced some skin discoloration and muscle cramping. During the first two years, she also reported having regular menstrual cycles.

About two years after she first started taking Gleevec, and about six months after the dose was increased, the woman reported that she was having irregular menstrual cycles and then her periods ceased altogether.

Doctors confirmed premature ovarian failure. While it's not possible to definitively prove that Gleevec caused premature menopause, Christopoulos said that based on the timing, the lack of other causes, and the drugs' mode of action, it's the most likely culprit.

Gleevec works by targeting tyrosine kinases, which are proteins that are very active in cancer cells. However, these proteins are also expressed by the ovaries.

"There are about 60 tyrosine kinases. Can Gleevec be so specific that it only interacts with one of the 60? This drug is pretty good at targeting and hitting the bull's-eye, but it's not perfect," said Dr. Bart Kamen, chief medical officer of the Leukemia & Lymphoma Society.

"Is it worth that risk? You better believe it," Kamen said. "The side effects of Gleevec compared to what else we do in cancer treatment is mild. It has a wonderful risk-to-benefit ratio."

"The advantages of this drug clearly outweigh the disadvantages," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

Brooks also pointed out that most women with CML are long past their reproductive years. According to the American Cancer Society, the average age of CML diagnosis is about 67.

While most women are already counseled about the risks to their fertility before undergoing any cancer treatment, Christopoulos said that women of reproductive age receiving Gleevec should know that they shouldn't become pregnant while taking the drug, and they may want to freeze some of their eggs before treatment.

More information

The American Cancer Society has more on Gleevec.

SOURCES: Constantinos Christopoulos, M.D., Ph.D., deputy director, 1st department of internal medicine, Amalia Fleming General Hospital, Athens, Greece; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Bart Kamen, M.D., chief medical officer and executive vice president, Leukemia & Lymphoma Society, White Plains, N.Y., and professor, pediatrics and pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Piscataway, N.J.; March 6, 2008, New England Journal of Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
2. Gleevec, the targeted cancer pill, delivers more good news to patients
3. Farm Bill Provision Will Disrupt MaineCare Program
4. Farm Bill Provision Will Disrupt Kentucky Medical Program
5. Farm Bill Provision Will Disrupt Kansas Medicaid Program
6. Farm Bill Provision Will Disrupt Iowa Medicaid and Food Stamp Programs
7. Farm Bill Provision Will Disrupt Illinois Medicaid Program
8. Farm Bill Provision Will Disrupt Georgia Medicaid Program
9. Farm Bill Provision Will Disrupt Food Stamp and Medicaid Programs
10. Farm Bill Provision Will Disrupt Delaware Medicaid Program
11. Farm Bill Provision Will Disrupt California Medicaid and Food Stamp Programs
Post Your Comments:
Related Image:
Gleevec May Disrupt Ovarian Function
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., ... and together with its subsidiaries, TriReme Medical LLC and ... company engaged in the design, assembly and distribution of ... vascular disease, is pleased to announce that a three-judge ... Court of Appeals for the Federal Circuit ("Federal Circuit") ...
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- Nautilus Medical Inc. today announced worldwide availability of ... ). The release of MatrixRay to the entire medical ... North America) in Chicago - ... --> --> MatrixRay is the ... studies worldwide via a peer-to-peer exchange network of physicians ...
Breaking Medicine Technology: